Dechert Secures Victory for Antares Pharma
February 26, 2021
Dechert LLP prevailed again in a putative securities class action alleging that Antares Pharma, Inc. and its Board of Directors made materially false and misleading statements about the likelihood of obtaining FDA approval of its drug, XYOSTED – a drug that was approved by the FDA shortly before plaintiff filed its amended complaint. After prevailing on our motion to dismiss the first and second amended complaints, the Plaintiff filed a third amended complaint, attempting to assert a claim under Section 10(b) of the Exchange Act and a control-person claim against the officer defendants for violation of Section 20(a) of the Exchange Act. Defendants moved to dismiss the third amended complaint, which the court granted on February 26, 2021.
The Dechert team included partners David Kistenbroker and Joni Jacobsen, and associates Melanie MacKay and Amy Lesperance.
About Dechert
Dechert is a leading global law firm with 26 offices around the world. We advise on matters and transactions of the greatest complexity, bringing energy, creativity and efficient management of legal issues to deliver commercial and practical advice for clients.
